Literature DB >> 4018780

Mesenchymal and muscle-specific intermediate filaments (vimentin and desmin) in relation to differentiation in childhood rhabdomyosarcomas.

W M Molenaar, J W Oosterhuis, A M Oosterhuis, F C Ramaekers.   

Abstract

Twenty-one childhood rhabdomyosarcomas were divided into three groups on the basis of cytologic composition. The tumors in group P consisted entirely of primitive mesenchymal cells, whereas those in groups M and W were characterized by the additional presence of numerous round rhabdomyoblasts and strap cells, respectively. The tumors were studied for the universal mesenchymal intermediate filament vimentin, and for the muscle-specific intermediate filament desmin. Vimentin positivity, which tended to be more prominent in primitive tumor cells, was found in all tumors, whereas desmin was found especially in round rhabdomyoblasts and strap cells. Desmin-positive primitive cells were found only in groups M and W, not in group P. It was concluded that the differentiation from primitive mesenchymal cells to morphologically recognizable myogenic tumor cells is accompanied by an increase in desmin positivity and, presumably, a decrease in vimentin positivity. Moreover, the observations suggest the existence of a group of "committed" cells that are morphologically primitive, but desmin-positive. These cells might play an important role in the observed further differentiation of rhabdomyosarcomas under chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018780     DOI: 10.1016/s0046-8177(85)80256-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  19 in total

Review 1.  The changing face of hepatic resection.

Authors:  S Iwatsuki; D G Sheahan; T E Starzl
Journal:  Curr Probl Surg       Date:  1989-05       Impact factor: 1.909

2.  Double and triple immunocytochemical labelling at the light microscope level in histopathology.

Authors:  T Krenács; L Krenács; B Bozóky; B Iványi
Journal:  Histochem J       Date:  1990-10

3.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  Diagnosis of rhabdomyosarcomas with HHF35, a monoclonal antibody directed against muscle actins.

Authors:  R A Schmidt; R Cone; J E Haas; A M Gown
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

5.  Antibody specific to muscle actins in the diagnosis and classification of soft tissue tumors.

Authors:  M Miettinen
Journal:  Am J Pathol       Date:  1988-01       Impact factor: 4.307

6.  HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues.

Authors:  T Tsukada; M A McNutt; R Ross; A M Gown
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

7.  Influence of dimethyl sulphoxide on intermediate filament proteins in human rhabdomyosarcoma cell lines: modulation at subcellular level.

Authors:  C Melguizo; J Prados; C Velez; A E Aranega; L Alvarez; A Aranega
Journal:  Histochem J       Date:  1994-06

8.  Human lung tumours may coexpress different classes of intermediate filaments.

Authors:  K C Gatter; M S Dunnill; G N Van Muijen; D Y Mason
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

9.  All histological types of primary human rhabdomyosarcoma express alpha-cardiac and not alpha-skeletal actin messenger RNA.

Authors:  W Schürch; M L Bochaton-Piallat; A Geinoz; E d'Amore; R N Laurini; M Cintorino; L R Bégin; Y Boivin; G Gabbiani
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

10.  Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas.

Authors:  O Skalli; G Gabbiani; F Babaï; T A Seemayer; G Pizzolato; W Schürch
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.